Great Novel Therapeutics Biotech & Medicals (TPEX:7427)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
32.80
-1.25 (-3.67%)
Mar 4, 2026, 2:06 PM CST
Market Cap1.46B -3.4%
Revenue (ttm)1.78M +189.6%
Net Income-87.75M
EPS-2.03
Shares Out42.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,000
Average Volume314,502
Open33.80
Previous Close34.05
Day's Range32.30 - 33.80
52-Week Range29.50 - 57.00
Beta-0.03
RSI45.55
Earnings DateMar 27, 2026

About TPEX:7427

Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. The company develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 15
Stock Exchange Taipei Exchange
Ticker Symbol 7427
Full Company Profile

Financial Performance

In 2024, TPEX:7427's revenue was 1.69 million, a decrease of -65.26% compared to the previous year's 4.85 million. Losses were -104.92 million, 72.0% more than in 2023.

Financial Statements